Cansino Biologics vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Cansino Biologics Inc (688185.CG)

Q3 202619 Jul – 4 Oct 2026

▲4

CanSino's pipeline expands, but mRNA cancer vaccine hopes stay early-stage

Meningococcal vaccine age expansion filed China's drug regulator accepted CanSino's application to widen the age range of its four-strain meningitis vaccine Manhaixin to 3 months–17 years. Approval would let it sell to more children and teens, supporting future revenue, though the company says it won't change current results.
A concrete regulatory step that can expand the market for an already-sold product.
DTP vaccine launches and adult version filed CanSino's infant DTP combination vaccine Pancocin began shipping after batch release, and a version for people aged six and older had its registration application accepted. These add real product sales and fill a gap in China's adult booster market, though profits will build over time.
Two pipeline milestones that turn into actual product supply and a new market segment.
mRNA cancer vaccine deal sparks huge rally After Moderna and Merck's cancer vaccine succeeded in a late-stage trial, CanSino signed a deal with Dephios Bio to co-develop a personalized mRNA cancer vaccine. The stock hit its 20% daily limit repeatedly, but the product is years from market and the company itself calls it early-stage.
The main force behind the period's sharp price moves, with an important early-stage caveat.
Government pharma plan lifts sector China's industry ministry and nine departments released a five-year plan targeting over 3.5 trillion yuan in drug industry revenue and faster innovative-drug growth. The policy boosted the whole biotech sector, and CanSino hit its 20% limit again, though this is sector-wide sentiment rather than company-specific news.
A policy catalyst that lifted CanSino along with peers, but not driven by its own results.

August 202619 Jul – 4 Oct 2026

▲4

CanSino's pipeline expands, but mRNA cancer vaccine hopes stay early-stage

Meningococcal vaccine age expansion filed China's drug regulator accepted CanSino's application to widen the age range of its four-strain meningitis vaccine Manhaixin to 3 months–17 years. Approval would let it sell to more children and teens, supporting future revenue, though the company says it won't change current results.
A concrete regulatory step that can expand the market for an already-sold product.
DTP vaccine launches and adult version filed CanSino's infant DTP combination vaccine Pancocin began shipping after batch release, and a version for people aged six and older had its registration application accepted. These add real product sales and fill a gap in China's adult booster market, though profits will build over time.
Two pipeline milestones that turn into actual product supply and a new market segment.
mRNA cancer vaccine deal sparks huge rally After Moderna and Merck's cancer vaccine succeeded in a late-stage trial, CanSino signed a deal with Dephios Bio to co-develop a personalized mRNA cancer vaccine. The stock hit its 20% daily limit repeatedly, but the product is years from market and the company itself calls it early-stage.
The main force behind the period's sharp price moves, with an important early-stage caveat.
Government pharma plan lifts sector China's industry ministry and nine departments released a five-year plan targeting over 3.5 trillion yuan in drug industry revenue and faster innovative-drug growth. The policy boosted the whole biotech sector, and CanSino hit its 20% limit again, though this is sector-wide sentiment rather than company-specific news.
A policy catalyst that lifted CanSino along with peers, but not driven by its own results.

Latest19 Jul – 4 Oct 2026

▲4

CanSino's pipeline expands, but mRNA cancer vaccine hopes stay early-stage

Meningococcal vaccine age expansion filed China's drug regulator accepted CanSino's application to widen the age range of its four-strain meningitis vaccine Manhaixin to 3 months–17 years. Approval would let it sell to more children and teens, supporting future revenue, though the company says it won't change current results.
A concrete regulatory step that can expand the market for an already-sold product.
DTP vaccine launches and adult version filed CanSino's infant DTP combination vaccine Pancocin began shipping after batch release, and a version for people aged six and older had its registration application accepted. These add real product sales and fill a gap in China's adult booster market, though profits will build over time.
Two pipeline milestones that turn into actual product supply and a new market segment.
mRNA cancer vaccine deal sparks huge rally After Moderna and Merck's cancer vaccine succeeded in a late-stage trial, CanSino signed a deal with Dephios Bio to co-develop a personalized mRNA cancer vaccine. The stock hit its 20% daily limit repeatedly, but the product is years from market and the company itself calls it early-stage.
The main force behind the period's sharp price moves, with an important early-stage caveat.
Government pharma plan lifts sector China's industry ministry and nine departments released a five-year plan targeting over 3.5 trillion yuan in drug industry revenue and faster innovative-drug growth. The policy boosted the whole biotech sector, and CanSino hit its 20% limit again, though this is sector-wide sentiment rather than company-specific news.
A policy catalyst that lifted CanSino along with peers, but not driven by its own results.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.